Therefore, the frequency of CTC/DTCs, the lack of EpCAM expression, the advent of targeted therapies, and the urgent need for additional therapeutic options for high risk patients make neuroblastoma an ideal disease in which to establish proof of principle for the capture and molecular analysis of DTCs. Here, EPCAM is linked to neuroblastoma.